What is Revvity's diagnostics — segment revenue?

Revvity (RVTY) reported diagnostics — segment revenue of $349.27M in Q1 2026.

How has Revvity's diagnostics — segment revenue changed year-over-year?

Revvity's diagnostics — segment revenue increased by 7.7% year-over-year, from $324.37M to $349.27M.

What is the long-term trend for Revvity's diagnostics — segment revenue?

Over 3 years (2022 to 2025), Revvity's diagnostics — segment revenue has grown at a -11.0% compound annual growth rate (CAGR), from $2.02B to $1.42B.

What does diagnostics — segment revenue mean?

Represents the total gross income generated by the diagnostics business segment from the sale of goods and services. This metric reflects the market demand for the company's immunodiagnostics, reproductive health, and applied genomics offerings.

Revvity (RVTY) Diagnostics — Segment revenue

Screener

Other segment segments

Life Sciences

$381.99M+1.9%

Similar metrics at other companies

BRCBReportable Segment — Segment revenue

$55.45M+23.7%

EVLVReportable Segment — Segment revenue

$46.33M+44.7%

BRCBStore revenue — Segment revenue

$55.38M+23.7%

BRCBOther — Segment revenue

$70K+52.2%

DFDVTreasury — Segment revenue

$2.4M—

DFDVReal Estate — Segment revenue

$262K-8.7%

Other financials

Income statement

See full

Revenue$711.1M+7.0%

Gross profit$387.7M+3.2%

Operating income$75.9M+5.1%

Net income$40.7M-3.6%

EPS (diluted)$0.36+2.9%

Balance sheet

See full

Cash & equivalents$861.5M-24.3%

Total debt$3.9B+17.8%

Total equity$7.2B-5.9%

Total assets$12.0B-2.9%

Cash flow

See full

Operating cash flow$115.2M-10.1%

CapEx$19.8M+23.7%

Free cash flow$95.5M-14.9%

Valuation

See full

Market cap$12.83B+28.7%

Enterprise value$15.91B+28.6%

P/E53.5×+18.6×

P/S4.4×+0.9×

Profitability

See full

Gross margin48.5%—

Operating margin12.4%-1.1pp

Net margin8.3%-2.1pp

FCF margin17%-1.9pp

Returns & leverage

See full

Return on equity3.2%-0.5pp

Debt / equity0.5×+0.1×

Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Revvity’s 10-Q, filed May 12, 2026.

Filed: May 12, 2026, 4:07 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0000031791-26-000019

Line item	Reportable Segments / Three Months Ended / April 5, 2026 / Life Sciences	Reportable Segments / Three Months Ended / April 5, 2026 / Diagnostics	Reportable Segments / Three Months Ended / April 5, 2026 / Total	Reportable Segments / Three Months Ended / March 30, 2025 / Life Sciences	Reportable Segments / Three Months Ended / March 30, 2025 / Diagnostics	Reportable Segments / Three Months Ended / March 30, 2025 / Total
Americas	$185,551	$130,441	$315,992	$184,279	$120,350	$304,629
Europe	91,695	131,351	223,046	76,022	105,770	181,792
Asia	84,599	87,481	172,080	80,094	98,247	178,341
	$361,845	$349,273	$711,118	$340,395	$324,367	$664,762
Major goods/service lines
Life Sciences Solutions	$299,996	—	$299,996	$286,453	—	$286,453
Software	61,849	—	61,849	53,942	—	53,942
Immunodiagnostics	—	201,831	201,831	—	197,562	197,562

Item 1.Unaudited Financial Statements

FAQ

What is Revvity's diagnostics — segment revenue?: Revvity (RVTY) reported diagnostics — segment revenue of $349.27M in Q1 2026.
How has Revvity's diagnostics — segment revenue changed year-over-year?: Revvity's diagnostics — segment revenue increased by 7.7% year-over-year, from $324.37M to $349.27M.
What is the long-term trend for Revvity's diagnostics — segment revenue?: Over 3 years (2022 to 2025), Revvity's diagnostics — segment revenue has grown at a -11.0% compound annual growth rate (CAGR), from $2.02B to $1.42B.
What does diagnostics — segment revenue mean?: Represents the total gross income generated by the diagnostics business segment from the sale of goods and services. This metric reflects the market demand for the company's immunodiagnostics, reproductive health, and applied genomics offerings.